首页 | 本学科首页   官方微博 | 高级检索  
检索        

急性髓系白血病患者hPer3基因启动子甲基化状态及其去甲基化对白血病细胞增殖的影响
作者姓名:Wang YK  Zhou JH  Zhou SQ  Fang GA  Li YW  Qiu L  Yang XC  Liu XG
作者单位:舟山医院,浙江省舟山市,316004
摘    要:目的 探讨急性髓系白血病(AML)患者hPer3基因启动子甲基化检测的临床意义,并观察地西他滨(DCA)诱导hPer3基冈表达对AML细胞系HL-60和U937增殖的影响.方法 应用甲基化聚合酶链反应(MS-PCR)和实时荧光定量PCR(RT-PCR)检测206例AML患者骨髓细胞hPer3基因启动子甲基化状态和mRNA表达,以40例缺铁性贫血患者骨髓细胞作为对照.用不同浓度的DCA处理HL-60和U937细胞48和72 h,检测其hPer3基因启动子甲基化状态及其mRNA表达,用MTT法检测细胞增殖抑制率,Annexin V-FITC/PI标记法检测细胞凋亡,用流式细胞术检测CD14、CD11b抗原表达.结果 AML患者初发组、部分缓解组、完全缓解组、复发组中,hPer3基因启动子甲基化阳性率分别为93.65%(63例中59例)、54.39%(57例中31例)、24.66%(73例中18例)、61.54%(13例中8例),对照组无一例甲基化;hPer3 mRNA表达分别为0.19±0.08、6.28±2.11、52.76±14.17、8.18±4.36,明显低于对照组(75.03±18.16),除部分缓解组与复发组相比差异无统计学意义(P>0.05)外,其余组别两两比较差异均有统计学意义(P<0.01).DCA处理HL-60和U937细胞后,hPer3基因启动子甲基化水平降低,mRNA表达升高,细胞出现凋亡,CD14和CD11b表达升高,并呈剂量和时间依赖性.结论 AML患者骨髓细胞hPer3基因启动子甲基化状态和mRNA表达水平可能作为AML患者病情缓解程度的一个评价指标.体外应用DCA有助于诱导hPer3基因表达和促AML细胞凋亡.
Abstract:
Objective To investigate the clinical significance of promoter methylation status of hPer3 gene in acute myeloid leukemia( AML) patients and the in vitro effect of decitabine( DCA) on AML cell lines HL-60 and U937. Methods The promoter methylation status of hPer3 gene and mRNA expression levels in bone marrow of 206 AML and 40 iron deficiency anemia( IDA) patients ( as control) were detected by methylation specific PCR(MS-PCR) and real-time PCR(RT-PCR). The HL-60 and U937 cell lines were treated with different concertrations of DCA for 48 and 72 h. The inhibition rates of cell proliferation were detected by methyl thiazolyl tetrazolium(MTT) ;the early apoptosis rates by staining with Annexin V and PI; the CD14 and CD11b expressions by flow cytometry( FCM) ; the promoter methylation status of hPer3 gene by MS-PCR;and the hPer3 mRNA expressions levels by RT-PCR. Results The promoter methylation rates of hPer3 in newly diagnosed( ND) group, partial remission ( PR) group, complete remission ( CR ) group, relapse (R)group and control group were 93.65% (59/63) ,54. 39% (31/57) ,24. 66% (18/73) ,61. 54% (8/13) and 0% (0/40), and the hPer3 mRNA expression levels were 0. 19 ±0.08,6.28 ±2. 11,52.76 ± 14.17,8. 18 ±4.36,75.03 ±18. 16, respeatively. There was a significant statistic difference between any two group (P <0.01) excepting for between PR and R group(P>0.05). After DCA treatment,the promoter hypermethylation status of hPer3 was reduced and the mRNA and CD14,CD11b expression levels were up regulated in a dose dependent manner with an induction of cell apoptosis. Conclusions Promoter methylation status and mRNA expression of hPer3 gene may be indicators for evaluating AML. DCA can induce the expression of hPer3 gene and cells apoptosis in AML.

关 键 词:基因  hPer3  白血病  非淋巴细胞  急性  甲基化聚合酶链反应  地西他滨

Promoter methylation status of hPer3 gene in AML patients and the in vitro effect of decitabine on the status
Wang YK,Zhou JH,Zhou SQ,Fang GA,Li YW,Qiu L,Yang XC,Liu XG.Promoter methylation status of hPer3 gene in AML patients and the in vitro effect of decitabine on the status[J].Chinese Journal of Hematology,2011,32(5):317-321.
Authors:Wang Ye-kai  Zhou Ji-hang  Zhou Shi-quan  Fang Guo-an  Li Yi-wei  Qiu Lei  Yang Xu-chun  Liu Xiao-guang
Institution:Zhoushan Hospital, Zhoushan 316004, China.
Abstract:Objective To investigate the clinical significance of promoter methylation status of hPer3 gene in acute myeloid leukemia( AML) patients and the in vitro effect of decitabine( DCA) on AML cell lines HL-60 and U937. Methods The promoter methylation status of hPer3 gene and mRNA expression levels in bone marrow of 206 AML and 40 iron deficiency anemia( IDA) patients ( as control) were detected by methylation specific PCR(MS-PCR) and real-time PCR(RT-PCR). The HL-60 and U937 cell lines were treated with different concertrations of DCA for 48 and 72 h. The inhibition rates of cell proliferation were detected by methyl thiazolyl tetrazolium(MTT) ;the early apoptosis rates by staining with Annexin V and PI; the CD14 and CD11b expressions by flow cytometry( FCM) ; the promoter methylation status of hPer3 gene by MS-PCR;and the hPer3 mRNA expressions levels by RT-PCR. Results The promoter methylation rates of hPer3 in newly diagnosed( ND) group, partial remission ( PR) group, complete remission ( CR ) group, relapse (R)group and control group were 93.65% (59/63) ,54. 39% (31/57) ,24. 66% (18/73) ,61. 54% (8/13) and 0% (0/40), and the hPer3 mRNA expression levels were 0. 19 ±0.08,6.28 ±2. 11,52.76 ± 14.17,8. 18 ±4.36,75.03 ±18. 16, respeatively. There was a significant statistic difference between any two group (P <0.01) excepting for between PR and R group(P>0.05). After DCA treatment,the promoter hypermethylation status of hPer3 was reduced and the mRNA and CD14,CD11b expression levels were up regulated in a dose dependent manner with an induction of cell apoptosis. Conclusions Promoter methylation status and mRNA expression of hPer3 gene may be indicators for evaluating AML. DCA can induce the expression of hPer3 gene and cells apoptosis in AML.
Keywords:Gene  hPer3  Leukemia  nonlymphocytic  acute  Methylation specific-PCR  Decitabine
本文献已被 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号